The Clinical Pharmacology of Etoposide and Teniposide

Clinical Pharmacokinetics

Volumn 12, Issue 4, 1987, Pages 223-252

  Clark, Peter I ^a,b   Slevin, Maurice L ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; PHENYTOIN; TENIPOSIDE; VINDESINE; WARFARIN;

ADVERSE DRUG REACTION; BIOAVAILABILITY; CANCER CHEMOTHERAPY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ADMINISTRATION; DRUG ANALYSIS; DRUG BILE LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MITOSIS; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW; THERAPY;

CHEMISTRY; DRUG STABILITY; ETOPOSIDE; HUMAN; KIDNEY; KINETICS; LIVER; PODOPHYLLOTOXIN; TENIPOSIDE;

EID: 0023235581     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-198712040-00001     Document Type: Review

References (237)

1. Continuous infusion teniposide (VM 26): a new effective schedule of administration in refractory leukaemias (AL) and neuroblastomas (NB)
2. Etoposide: chemistry, preclinical and clinical pharmacology
3. A radioimmunoassay for VP-16-213 in plasma
4. Cellular pharmacokinetics of two epipodophyllotoxin glucopyranoside derivatives, VM26 and VP16: uptake in the presence and absence of human serum albumin
5. The role of drug disposition kinetics on cellular transport of the anti-neoplastic agent VM-26
6. Comparison of uptake and binding of two epipodophyllotoxin glucopyranosides, 4′-demethyl epipodophyllotoxin thenylidene- β-D-glucoside and 4′-demethyl epipodophyllotoxin ethylidene β-D-glucoside, in the L1210 leukaemia cell
7. Analysis of 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-β-D-glucopyranoside) by high-performance liquid chromatography
8. Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives
9. 4′-demethyl-epipodophyllic acid-9-(4,6-O-ethylidene-beta-D-glucopyranoside), the major urinary metabolite of VP 16-213 in man
10. Mechanism of cellular transport of two epipodophyllotoxin glucopyranoside derivatives, VM26 and VP16
11. Combination chemotherapy of the epipodophyllotoxin derivatives teniposide and etoposide
12. Pharmacokinetics of etoposide (VP) in patients with normal and abnormal liver function
13. Podophyllotoxin derivative VP 16-213
14. Pharmacokinetics of VP 16-213 using a new HPLC assay
15. Etoposide: a new anti-cancer agent
16. Interaction of VP 16-213 with DNA repair antagonists
17. Interaction of VP16-213 with the DNA repair antagonist chloroquine
18. Modification of the pendant ring of podophyllotoxin
19. The effect of etoposide on human CFU-GM
20. Cell cycle and stage-dependent induction of G2 phase arrest by different antitumour agents
21. Effect of VP-16-213 on NBT reduction in the normal polymorphonuclear neutrophil
22. Phase 1 clinical and pharmacological study of continuous infusion (CI) etoposide (VP16) in patients with advanced cancer
23. New American remedies. I. Podophyllum peltatum
24. Phase II study of VM-26 in acute leukaemia, neuroblastoma and other preparatory childhood malignancies: a report from the Children’s Cancer Study Group
25. Conformational analysis of podophyllotoxin and its congeners. Structure-activity relationship in microtubule assembly
26. Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma
27. Comparison of the biologic activity of VP16-213 given i.v. and orally in capsules or drink ampoules
28. Rationale of combination chemotherapy
29. High performance liquid chromatography of podophyllotoxins and related ligands
30. Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma
31. Quantification of teniposide in human serum by high-performance liquid chromatography with electrochemical detection
32. Current development of podophyllotoxins
33. Anti-metastatic effect of two derivatives of epipodophyllotoxin in mice
34. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomised trial using three dosage schedules
35. VP16-213 (Etoposide). A critical review of its activity
36. Human anticancer effect of podophyllum derivatives (SPG and SPI)
37. Phase II study of VP16-213 in childhood malignant disease: children’s cancer study group report
38. Non-intercalative antitumour drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II
39. Influence of treatment schedule on the toxicity and anti-tumour activity of mitotic inhibitors and semisynthetic podophyllotoxin derivatives
40. Leech book of Bald
41. Comparison between VP16 and VM26 in Lewis lung carcinoma of mouse
42. Comparison of pharmacokinetics of VP 16 in mice, rats and humans
43. Metabolic studies of a podophyllotoxin derivative (VP16) in the isolated perfused liver
44. The action of podophyllotoxin and its fractions on marine eggs
45. The clinical pharmacology of VM-26 and VP16-213: a brief overview
46. EPEG, a new anti-neoplastic epipodophyllotoxin
47. PTG, a new anti-neoplastic epipodophyllotoxin
48. Enhanced cytotoxicity of fluoropyrimidines by etoposide in L1210 cells
49. Drug monitoring of etoposide (VP16-213)
50. Studies of resistance and cross resistance to vincristine (VCR), VM-26 and VP-16-213 in human leukemic cells (CEM)
51. Anti-mitotic substances
52. In vitro cytotoxicity of VP16 on primary tumour and metabolism of Lewis lung carcinoma
53. Pharmacokinetics of VP16-213 given by different administration methods
54. Podophyllotoxin derivatives VP16 and VM26
55. Pharmacokinetics of teniposide in patients with ovarian cancer
56. Clinical pharmacokinetics of VP16
57. Pharmacokinetics of etoposide in gastrochondrocarcinoma
58. Schedule dependency of the antileukaemic activity of the podophyllotoxin-derivative VP 16-213 (NSC 141540) in L1210 leukaemia
59. Clinical investigation of a new podophyllin derivative, epipodophyllotoxin 4′-demethyl-l-9-(4,6-0-2-hemylidene- β-D-glucopyranoside) [NSC-122819] in patients with malignant lymphomas and solid tumours
60. Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4′-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene- β-D-glucopyranoside) and 4′-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene- β-D-glucopyranoside) and their metabolites on human leukaemic lymphoblasts
61. Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213
62. Pilot study to determine an intermittent dose schedule for VP16-213
63. Pharmacokinetics of etoposide (VP) in patients with small cell lung cancer
64. Flow cytometric analysis of DNA distribution after VP 1-213 treatment on Lewis lung carcinoma
65. Pharmacokinetics of teniposide (VM-26) and etoposide (VP16-213) in children with cancer
66. Clinical pharmacology of VM-26 (NSC 12819) and VP-16 (NSC 141540) in children with cancer
67. A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin- β-D-ethylidene glucoside (NSC 141540) VP 16-213
68. High performance liquid chromatography determination of 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene- β-D-glucopyranoside) (VP-16-213)
69. Radiation recall associated with VP-16-213 therapy
70. Nonenolizable podophyllotoxin derivatives
71. Overview of drug protein binding
72. Characterisation of VP-16 induced DNA damage in isolated L1210 nuclei
73. Characterisation of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity
74. Cross reactivity to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target
75. Inhibition of NADH-linked respiration with the anticancer agent 4′-demethyl-epipodophyllotoxin hemylidene glucoside (VM26)
76. A quantitative microdensitometric and autoradiographic study of the effect of 4′-demethyl-epipodophyllotoxin- β-D-thenylidene glucoside (VM-26) on the cell cycle of cultured fibroblasts
77. Effect of α-peltatin, β-peltatin and podophyllotoxin on lymphoma and other transplanted tumors
78. Effects of an epipodophyllotoxin derivative (VP-16-213) on macromolecular synthesis and mitosis in mastocytoma cells in vitro
79. Comparative study of the early effects of epipodophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures
80. Genetic, biochemical and cross resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs VM-26 and VP16-213
81. Synthesis and VM26- and VP-16-213-like activities of different glycosidic derivatives of epipodophyllotoxin and its 4′-demethyl analog
82. Determination of VP16-213 concentrations using an enzyme linked immunosorbent assay (ELISA)
83. Clinical pharmacology of high dose VP 16-213
84. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients
85. Biliary clearance and hepatic metabolism of etoposide (VP-16)
86. Evidence for glucuronidation of etoposide
87. High-performance liquid chromatography of etoposide in plasma and urine
88. The pharmacokinetics of oral etoposide (VP16-213)
89. The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide
90. The effect of dose on the bioavailability of oral etoposide
91. Variable bioavailability following repeated oral doses of etoposide
92. Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies
93. Continuous intravenous infusions of (etoposide) VP-16-213 in patients with advanced malignancies
94. A comparative assessment of the in vitro effects of drugs on cells by means of colony assays of flow microfluorimetry
95. Clinical pharmacology of etoposide by radioimmunoassay
96. Radioimmunoassay for etoposide and teniposide
97. Pharmacokinetics of high dose etoposide (VP-16)
98. Pharmacokinetics of high dose teniposide (VM 26)
99. Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detection
100. Pharmacokinetics and evaluation of increasing dosage of etoposide in a chronic hemodialysis patient
101. Analysis of etoposide (VP 16) and possible metabolites in biological fluids by HPLC with electrochemical detection
102. A sensitive high-performance liquid Chromatographic method for the analysis of the anti-neoplastic agents VP-16-213 and VM-26 in biological fluids
103. Effects of a new antitumor agent epipodophyllotoxin on growth and chromosomes in human hemopoietic cell lines
104. Pharmacokinetics of etoposide (VP-16) in children with refractory solid tumours
105. The podophyllotoxin derivatives VP-16 and VM-26
106. Etoposide (VP-16-213)
107. Etoposide (VP-16-213) and teniposide (VM-26): comparative in vitro activities in human tumors
108. Do aloes and podophyllum (Carter’s Little Liver Pills) increase the flow of bile into the duodenum?
109. Synergistic antitumor activity of vincristine and VP-16-213
110. 1H NMR spectra, and activity of delactonised derivatives of anticancer drug etoposide
111. A case report and description of the pharmacokinetic behavior of intrapleurally distilled etoposide
112. Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts
113. Comparison of DNA inhibitory effects of VP16 and its two isomers in cultured human leukemia cells
114. Condyloma acuminata
115. Resistance to VP16-213 and VM26 is localised to nuclei of resistant human lung and colon carcinoma cell lines
116. Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute non-lymphocytic leukemia
117. Clinical pharmacology and intracerebral tumor penetration of 4′-demethyl epipodophyllotoxin-9-(4,6-O-ethylidene- β-D-glucopyranoside) (VP-16 NSC-141540)
118. VM-26: phase I and II studies
119. Pharmacokinetic consequences of drug displacement from blood and tissue proteins
120. Etoposide-based combination chemotherapy for extensive small cell lung cancer (SCLC): randomisation between one or five days oral etoposide
121. Inhibition by 4′-demethyl-epipodophyllotoxin 9-(4,6-O-2-thenylidene- β-D-glucopyranoside) of human lymphoblast cultures in G2 phase of the cell cycle
122. Nucleoside transport in mammalian cells: inhibition by colchicine
123. Phase-1 clinical trial of an oral solution of VP16-213
124. The epidodophyllotoxin derivatives VM-26 and VP-16-213, 1976–1979; a review
125. Clinical trial of the oral form of a new podophyllotoxin derivative VP 16-213 (NSC 141540) in patients with advanced neoplastic disease
126. Phase I clinical trial of a new antitumor agent: 4′-demethylepipodohyllotoxin 9-(4,6-O-ethylidene- β-D-glueopyranoside)
127. Teniposide: A review of 12 years of experience
128. Etoposide (VP-16-213): current status of an active anti-cancer drug
129. Multicompartment pharmacokinetic model for 4′-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- β-D glucopyranoside) in humans
130. The absolute oral bioavailability and pharmacokinetics of etoposide
131. Tubulin binding affinities of podophyllotoxin and colchicine analogues
132. Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin
133. The biological effects and the chemical composition of podophyllin: a review
134. Cytotoxicity and extent of protein associated DNA strand breaks by etoposide (VP-16-213) and teniposide (VM-26) and their quinone metabolites in a human breast cancer cell line
135. The similarity of the effect of podophyllotoxin and colchicine and their use in the treatment of condylomata acuminata
136. Photofluorometric studies on action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts
137. Phase 1 trial of a new form of an oral administration of VP-16-213
138. Pharmacokinetics and bioavailability of VP-16-213 in man
139. Uptake as a determinant of resistance to teniposide (VM-26)
140. Altered flux of teniposide (VM-26) across the cell membrane of L1210/VM-26 sublines
141. Damage induced in sarcoma 37 with podophyllin, podophyllotoxin, α-peltatin, β-peltatin and quercetin
142. Orcadian rhythm in tolerance of mice for etoposide
143. High performance liquid Chromatographic determination of etoposide in plasma using electrochemical detection
144. VP-16-213 and podophyllotoxin: a study on the relationship between chemical structure and biological activity
145. Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in Hela cells
146. Effect of VP-16-213 on the intracellular degradation of DNA in Hela cells
147. Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners
148. Medicinal plants of our Maine Indians
149. Inhibition of topoisomerase II by VP-16-213 (Etoposide), VM-26 (Teniposide) and structural congeners as an explanation for in vivo DNA breakage and cytotoxicity
150. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship
151. Phorbol myristate acetate stimulates microtubule and 10-nm filament extension and lysosome redistribution in mouse macrophages
152. Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration
153. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin’s lymphomas, and other malignancies
154. Pharmacological studies on VM-26 (teniposide)
155. Determination of etoposide (VP16-213) and teniposide (VM26) in serum by high-performance liquid chromatography with electrochemical detection
156. Response of L1210 to combination of cytosine arabinoside and VM 26 or VP 16-213
157. VM-26 and cytosine arabinoside combination chemotherapy for initial induction: failures in childhood lymphocytic leukaemia
158. Sedimentation of DNA from L1210 cells after treatment with 4′demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene- β-D-glucopyranoside) and l- β-D-arabinofur-anosylcytosine or both drugs
159. Teniposideresistance i.e. multifaceted in L1210 cells
160. Interpatient pharmacokinetic variability of teniposide (VM26) during prolonged continuous infusion in pediatric patients
161. Comparison of the potential of the two epipodophyllotoxin derivatives VP-16 and VM-26 on small cell cancer of the lung (SCLC) cell lines
162. A mammalian topoisomerase — possible relationship to intercalator-induced DNA strand breakage
163. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage
164. Pharmacokinetic study of VM-26 given as a prolonged i.v. infusion to ovarian cancer patients
165. Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA damage
166. VM-26 and VP-16-213: a comparative analysis
167. Clinical pharmacology of intra-carotid etoposide
168. VP-16 pharmacokinetics in adults with cancer as determined by a new high pressure liquid chromatography (HPLC) assay
169. Absorption of etoposide (VP-16-213) from the small intestine of the rat: the potential role of mucus as an absorption rate-limiting barrier
170. In vivo resistance towards anthracyclines, etoposide and cis-diamminedichloro-platinum (II)
171. Drug interactions with warfarin
172. Pharmacokinetics of VM26 after 60 minutes or 24 hour infusion
173. Pharmacokinetics of VP16 in patients with impaired renal function
174. Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatoid exchanges in Chinese hamster ovary cells
175. Free radical metabolism of VP-16 and inhibition of anthracycline-induced lipid peroxidation
176. Microsomal interactions and inhibition of lipid peroxidation by etoposide (VP-16,213): implications for mode of action
177. Etoposide: a semi-synthetic epipodophyllotoxin
178. Effects of different extracellular protein concentrations (conc) on the in vivo uptake of antitumor drugs that are extensively protein bound (PB): etoposide (VP16) and teniposide (VM26)
179. High-performance liquid Chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection
180. Pharmacokinetics of etoposide (VP 16) in children and adolescents with refractory solid tumors
181. Teniposide (VM 26) disposition in children with leukemia
182. Verapamil potentiation of VP-16-213 in acute lymphatic leukemia (ALL) in vivo and reversal of pleiotropic drug resistance
183. A randomised trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer
184. The effect of dose on the bioavailability of oral etoposide
185. Bioavailability and pharmacokinetics of etoposide (VP-16)
186. Kinetics of VP-16 epipodophyllotoxin in children with cancer
187. Etoposide-induced blood-brain barrier disruption: effect of drug compared with that of solvents
188. Effect of intra-carotid etoposide on opening the blood-brain barrier
189. Etoposide induced blood-brain barrier disruption in rats: duration of gening and histological sequelae
190. 4′-demethyl-epipodophyllotoxin thenylidene glucoside (VM-26), a podophyllum compound with a new mechanism of action
191. Activity of new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumours
192. Effects of the epipodophyllotoxin derivative VM-26 on mitosis and interphase
193. Etoposide infusions for treatment of metastatic lung cancer
194. VP-16 (VP) and VM-26 (VM) penetration into human brain tumors (BT)
195. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumours
196. Penetration of teniposide (VM-26) into human intracerebral tumours
197. Bioavailability, pharmacokinetics and clinical effects of an oral preparation of etoposide
198. Analysis of the anticancer drugs etoposide (VP-16-213) and teniposide (VM-26) by high performance liquid chromatography with fluorescence
199. Analysis of the anticancer drugs VP-16-213 and VM-26 and their metabolites by high performance liquid chromatography
200. The cytological effects of podophyllin
201. Pharmacokinetics study with high dose etoposide infusion in patients with small cell lung cancer
202. Selective oxic cytotoxicity of VP-16-213: enhancement of antitumour activity by a perfluorochemical emulsion/oxygen
203. Analysis and degradation kinetics of etoposide (VP16-213) in aqueous solution
204. Clinical studies with podophyllin compounds SPI-77 (NSC-72274) and SPG-837 (42076)
205. In vitro and in vivo metabolism of VP-16-213 in the rat
206. Role of bioactivation in covalent binding of VP-16 to rat liver and Hela cell microsomal proteins
207. Inactivation of X174 DNA by the ortho-quinone derivative or its reduction product, of the antitumor agent VP16-213
208. The role of metabolic activation by cytochrome P-450 in covalent binding of VP-16-213 to rat liver and Hela cell microsomal proteins
209. Treatment schedule dependency of experimentally active anti-leukemic (L1210) drugs
210. VP-16-213 (Etoposide): The mandrake root from Issyk-kul
211. Combination chemotherapy with hexamethylmelamine in L1210 and P388 leukemias
212. Comparison of CSF penetration of VP-16 by intracarotid (IC), intravenous (IV) and intraventricular (IT) routes in dogs
213. Warfarin, etoposide and vindesine interactions
214. Automated liquid Chromatographic analysis of the anti-tumorigenic drugs, etoposide (VP16-213) and teniposide (VM26)
215. Partial cross-resistance of cultured murine leukaemia vincristine-resistant P388 cells to 4′-demethylepipodophyllotoxin ethylidine-β-D-glucoside
216. Interaction of drugs with microtubular proteins
217. Biochemical and pharmacological properties of microtubules
218. The biochemical events of mitosis. II. The in vivo and in vitro binding of colchicine in grasshopper embryos: its possible relation to inhibition of mitosis
219. Free radical scavengers inhibit VP-16 induced DNA damage and cytotoxicity
220. Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents
221. DNA damage as a basis for 4′-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene- β-D-glucopyranoside) (etoposide) cytotoxicity
222. Effects of microtubule inhibitors (MI) on etoposide (VP-16) uptake and DNA damage
223. Tenoposide (VM26) and etoposide (VP-16-213)-induced augmentation of methotrexate transport and polyglutamation in Ehrlich ascites tumor cells in vitro
224. Analysis of the inhibitory effects of VP-16-213 (etoposide) and podophyllotoxin on thymidine transport and metabolism in Ehrlich ascites tumor cells in vitro
225. Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro
226. Verapamil-induced augmentation of etoposide accumulation of L1210 cells in vitro
227. Effects of verapamil on etoposide, vincristine and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukaemia cells in vitro
228. Role of VM-26 on glioma cells in vitro analysis of GO cells and recruitment
229. Identification of DNA topoisomerase II as an intracellular target of antitumour epipodophyllotoxins in Simian virus 40-infected monkey cells
230. Phase I pharmacokinetic study of intraperitoneal (ip) cisplatin (DDP) and etoposide (VP-16)